variant pharmaceuticals is an orphan drug company leveraging advanced proprietary technologies to develop best-in-class drugs for patients with rare diseases. our accomplished leadership team, each with more than 15 years of demonstrated success in the biopharmaceutical and medical industries, focuses on assuring that our development efforts serve the needs of all our stakeholders: patients, health care providers, payors, and our investors. our evolving product pipeline is targeted to the $100+ billion orphan drug market. our lead orphan drug candidate is hydroxypropyl beta cyclodextrin (hpβcd) for chronic treatment of two orphan indications, var 200: focal segmental glomerulosclerosis (fsgs) and var 300: alport syndrome (as). both of these conditions are rare progressive forms of kidney disease associated with accumulation of cholesterol and lipids, contributing to impaired kidney function, ultimately leading to dialysis and/or kidney transplantation. hpβcd entraps and removes lipids
Company profile
Ticker
ZVSA
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Larkspur Health Acquisition Corp.
SEC CIK
Corporate docs
IRS number
862685744
ZVSA stock data
Latest filings (excl ownership)
8-K
Material Modifications to Rights of Security Holders
25 Apr 24
8-K
Submission of Matters to a Vote of Security Holders
17 Apr 24
DEFA14A
Additional proxy soliciting materials
27 Mar 24
10-K
2023 FY
Annual report
25 Mar 24
DEF 14A
Definitive proxy
19 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Mar 24
PRE 14A
Preliminary proxy
8 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Mar 24
S-8
Registration of securities for employees
14 Feb 24
8-K
Changes in Registrant's Certifying Accountant
22 Dec 23
Latest ownership filings
SC 13G/A
Ionic Ventures, LLC
14 Feb 24
SC 13G
Anson Funds Management LP
14 Feb 24
SC 13G/A
L1 Capital Global Opportunities Master Fund, Ltd.
9 Feb 24
SC 13G/A
INCON Co., Ltd.
19 Jan 24
4
Change in insider ownership
3 Aug 23
SC 13G
L1 Capital Global Opportunities Master Fund, Ltd.
18 Jul 23
SC 13D/A
Glover Stephen C.
12 May 23
SC 13D/A
O'Connor Daniel J.
12 May 23
SC 13G
Ionic Ventures, LLC
3 May 23
SC 13G/A
Oaktree Capital Group, LLC
14 Feb 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 14 |
Opened positions | 8 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 42.21 mm |
Total shares | 8.78 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
IOI Ionic Ventures | 2.11 mm | $979.00 k |
L1 Capital Global Opportunities Master Fund | 2.03 mm | $518.00 k |
INCON | 1.95 mm | $0.00 |
O'Connor Daniel J. | 1.55 mm | $722.00 k |
A.g.p. / Alliance Global Partners | 849.49 k | $0.00 |
VIRT Virtu Financial | 120.38 k | $30.00 k |
Cowen And | 50.00 k | $12.28 mm |
Two Sigma Securities | 39.50 k | $9.70 mm |
Cubist Systematic Strategies | 36.87 k | $9.05 mm |
Vanguard | 17.19 k | $4.22 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Jan 23 | Pablo A. Guzman | Stock Options Common Stock | Grant | Acquire A | No | No | 2.11 | 100,000 | 211.00 k | 100,000 |
News
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions In Patients With Diabetes
4 Apr 24
HC Wainwright & Co. Reiterates Buy on ZyVersa Therapeutics, Maintains $12 Price Target
26 Mar 24
HC Wainwright & Co. Maintains Buy on ZyVersa Therapeutics, Lowers Price Target to $12
12 Mar 24
12 Health Care Stocks Moving In Thursday's Intraday Session
7 Mar 24
HC Wainwright & Co. Reiterates Buy on ZyVersa Therapeutics, Maintains $24 Price Target
29 Feb 24
Press releases
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
4 Apr 24
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
25 Mar 24
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled "Inflammation Illuminated,"at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024
14 Mar 24
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
29 Feb 24
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
28 Feb 24